Establishment of a tear protein biomarker panel differentiating between Graves’ disease with or without orbitopathy

@inproceedings{Aass2017EstablishmentOA,
  title={Establishment of a tear protein biomarker panel differentiating between Graves’ disease with or without orbitopathy},
  author={Cecilie Aass and Ingrid Norheim and Erik Fink Eriksen and Ellen Charlotte B{\o}rnick and Per Medb{\o}e Thorsby and Milaim Pepaj},
  booktitle={PloS one},
  year={2017}
}
BACKGROUND Graves' orbitopathy (GO) is an autoimmune inflammatory ocular complication and one of the most frequent manifestations of Graves' disease (GD). Clinical judgment of GO is subjective sometimes leading to clinical and therapeutic challenges. Better tools to diagnose this severe complication are warranted. PATIENTS AND METHODS The aim of the present study was to evaluate tear levels of LYZ, LACRT and AZGP1 in GD patients with or without GO, as possible biomarkers for GO. Tear samples… CONTINUE READING

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Quantification of 47 human tear proteins using high resolution multiple reaction monitoring ( HRMRM ) basedmass spectrometry

L Tong, XY Zhou, +3 authors SK Koh
  • Journal of Proteome
  • 2014

Clinical manifestations . A multidisciplinary approachquestions and answers

AJ Dickinson
  • 2010

Graves' ophthalmopathy.

  • The New England journal of medicine
  • 2010

Similar Papers

Loading similar papers…